ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO282

The Effect of Extracorporeal Shock Wave Therapy in Hemodialysis Patients: A Randomized Controlled Trial

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Kim, Do Hyoung, Hallym University Hangang Sacred Heart Hospital, Seoul, Korea (the Republic of)
  • Kee, Younkyung, Hallym University Hangang Sacred Heart Hospital, Seoul, Korea (the Republic of)
Background

Muscle wasting is a common feature in the hemodialysis (HD) patients and associated with comorbid complications, poor quality of life, frailty and premature death. Extracorporeal Shock-Wave Therapy (ESWT) is able to relief pain, as well to positively regulate inflammation (probably as immunomodulator), to induce neoangiogenesis and stem cells activities, thus improving tissue regeneration and healing, and has the advantages of easy application, and minimal risks for these patients. This study aimed to evaluate the effects of intradialytic ESWT.

Methods

This was a single center, prospective, randomized controlled trial. Seventeen HD patients were randomly assigned to either the ESWT group or the control group. The ESWT group received intradialytic ESWT over a 12-week period. Measurement of body composition using a dural energy X-ray absorptiometry, the handgrip strength test, gait speed test, five time sit to stand test, and the timed up and go test for physical function assessment, and blood tests were performed before and after the intervention period.

Results

The ESWT group demonstrated significant improvement compared with the control group in main functional parameters: decreased time in gait speed test (5.5 ± 13.3 vs. -0.5 ± 1.3 sec), five time sit to stand test (3.9 ± 10.7 vs. -1.4 ± 2.8 sec), and the timed up and go test (6.9 ± 17.8 vs. -3.1 ± 4.2 sec). After treatment, lipopolysaccharide concentrations were reduced, and glutathione peroxidase concentrations were increased significantly in ESWT group. However, there was no significant difference in muscle mass and other blood tests.

Conclusion

The ESWT group showed improvement after intervention in physical function test, and oxidative stress parameters. ESWT could be an effective treatment tool for HD patients with either muscle wasting, weakness, or sarcopenia.